Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Braz. j. med. biol. res ; 48(6): 528-536, 06/2015. tab, graf
Article in English | LILACS | ID: lil-748220

ABSTRACT

This study aimed to determine the role of mitochondrial adenosine triphosphate-sensitive potassium (mitoKATP) channels and protein kinase C (PKC)-ε in the delayed protective effects of sevoflurane preconditioning using Langendorff isolated heart perfusion models. Fifty-four isolated perfused rat hearts were randomly divided into 6 groups (n=9). The rats were exposed for 60 min to 2.5% sevoflurane (the second window of protection group, SWOP group) or 33% oxygen inhalation (I/R group) 24 h before coronary occlusion. The control group (CON) and the sevoflurane group (SEVO) group were exposed to 33% oxygen and 2.5% sevoflurane for 60 min, respectively, without coronary occlusion. The mitoKATP channel inhibitor 5-hydroxydecanoate (5-HD) was given 30 min before sevoflurane preconditioning (5-HD+SWOP group). Cardiac function indices, infarct sizes, serum cardiac troponin I (cTnI) concentrations, and the expression levels of phosphorylated PKC-ε (p-PKC-ε) and caspase-8 were measured. Cardiac function was unchanged, p-PKC-ε expression was upregulated, caspase-8 expression was downregulated, cTnI concentrations were decreased, and the infarcts were significantly smaller (P<0.05) in the SWOP group compared with the I/R group. Cardiac function was worse, p-PKC-ε expression was downregulated, caspase-8 expression was upregulated, cTnI concentration was increased and infarcts were larger in the 5-HD+SWOP group (P<0.05) compared with the SWOP group. The results suggest that mitoKATP channels are involved in the myocardial protective effects of sevoflurane in preconditioning against I/R injury, by regulating PKC-ε phosphorylation before ischemia, and by downregulating caspase-8 during reperfusion.


Subject(s)
Animals , Male , Ischemic Preconditioning, Myocardial/methods , Methyl Ethers/pharmacology , Myocardial Reperfusion Injury/prevention & control , Platelet Aggregation Inhibitors/pharmacology , Potassium Channels/pharmacology , Protein Kinase C/pharmacology , Anti-Arrhythmia Agents/pharmacology , Blotting, Western , /analysis , Decanoic Acids/pharmacology , Heart/drug effects , Heart/physiopathology , Hemodynamics/drug effects , Hydroxy Acids/pharmacology , Ischemia/prevention & control , Protective Agents/pharmacology , Random Allocation , Rats, Sprague-Dawley , Reproducibility of Results , Time Factors , Troponin I/analysis
SELECTION OF CITATIONS
SEARCH DETAIL